Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REGN Regeneron Pharmaceuticals

Market Closed 06-05 16:00:00 EDT

635.45

+6.72

+1.07%

盘后632.05

-3.40-0.54%

19:53 EDT

High640.82	Low632.09	Vol975.79K
Open632.26	D1 Closing628.73	Amplitude1.39%
Mkt Cap67.18B	Tradable Cap65.64B	Total Shares105.72M
T/O620.67M	T/O Rate0.94%	Tradable Shares103.30M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"Regeneron Pharmaceuticals","latestPrice":635.45,"timestamp":1780689600000,"preClose":628.73,"halted":0,"volume":975793,"hourTrading":{"tag":"盘后","latestPrice":632.05,"preClose":635.45,"latestTime":"19:53 EDT","volume":52032,"amount":33062329.5976,"timestamp":1780703625037,"change":-3.4,"changeRate":-0.005351,"amplitude":0.005351},"delay":0,"changeRate":0.010688212746329947,"floatShares":103302739,"shares":105719806,"eps":41.06084,"marketStatus":"Market Closed","change":6.72,"latestTime":"06-05 16:00:00 EDT","open":632.26,"high":640.82,"low":632.09,"amount":620668847.9173,"amplitude":0.013885,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":41.06084,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780905600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":628.73,"dividendRate":0.00564,"preHourTrading":{"tag":"盘前","latestPrice":632,"preClose":628.73,"latestTime":"09:29 EDT","volume":152,"amount":95938.32639999999,"timestamp":1780666173000,"change":3.27,"changeRate":0.005201,"amplitude":0.021567},"postHourTrading":{"tag":"盘后","latestPrice":632.05,"preClose":635.45,"latestTime":"19:53 EDT","volume":52032,"amount":33062329.5976,"timestamp":1780703625037,"change":-3.4,"changeRate":-0.005351,"amplitude":0.005351},"volumeRatio":0.7748755250851689,"impliedVol":0.2927,"impliedVolPercentile":0.0558},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"2641140137","title":"Regeneron Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2641140137","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641140137?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:46","pubTimestamp":1780692360,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  advanced 1.07% to $635.45 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index  falling 2.64% to 7,383.74 and Dow Jones Industrial Average  falling 1.35% to 50,866.78.This was the stock's fourth consecutive day of gains.Regeneron Pharmaceuticals Inc. closed 22.61% short of its 52-week high of $821.11, which the company reached on January 9th.The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Amgen Inc.  rose 1.15% to $349.58, Moderna Inc.  fell 8.04% to $47.44, and Gilead Sciences Inc.  fell 0.02% to $129.16.Trading volume  eclipsed its 50-day average volume of 898,755.Data source: Dow Jones Market Data, FactSet. Data compiled June 5, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641197658","title":"Regeneron Pharmaceuticals (REGN) Valuation Check After CytomX Collaboration Expansion And Lynozyfic Trial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2641197658","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641197658?lang=en_us&edition=fundamental","pubTime":"2026-06-05 13:35","pubTimestamp":1780637750,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) is back in focus after expanding its cancer research partnership with CytomX Therapeutics and reporting early clinical results for Lynozyfic in light chain amyloidosis, which together have supported fresh interest in the stock.\nSee our latest analysis for Regeneron Pharmaceuticals.\nDespite the positive reaction to the CytomX expansion and Lynozyfic data, Regeneron’s 1-day share price return of 1.58% sits against a year-to-date share price decline of 19.01%...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-valuation-check-after-cytomx","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-valuation-check-after-cytomx","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2023250504.SGD","LU0109394709.USD","BK4139","LU0114720955.EUR","BK4588","LU2089984988.USD","LU0882574055.USD","LU0320765992.SGD","LU0058720904.USD","REGN","LU2362541273.HKD","LU0289739699.SGD","LU0823416689.USD","LU0823434583.USD","LU2362540622.SGD","BK4585","LU1917777945.USD","LU0889565916.HKD","LU2237438978.USD","LU0823434740.USD","LU2106854487.HKD","LU2362541513.USD","LU1974910355.USD","LU2468319806.SGD","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640548551","title":"Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO","url":"https://stock-news.laohu8.com/highlight/detail?id=2640548551","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640548551?lang=en_us&edition=fundamental","pubTime":"2026-06-04 19:00","pubTimestamp":1780570800,"startTime":"0","endTime":"0","summary":"Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needsTARRYTOWN, N.Y., June  04, 2026  (GLOBE NEWSWIRE","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/04/3306640/0/en/Regeneron-to-Highlight-Progress-Across-Its-Metabolic-Disease-Ophthalmology-and-Rare-Disease-Pipelines-at-ADA-and-ENDO.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434583.USD","BK4588","LU0320765992.SGD","LU2106854487.HKD","REGN","BK4139","LU0882574055.USD","LU2089984988.USD","LU2065732104.USD","LU2468319806.SGD","LU0114720955.EUR","LU2362540622.SGD","BK4097","BK4183","LU0053666078.USD","LU0289739699.SGD","LU2362541273.HKD","LU2023250504.SGD","LU0889565916.HKD","LU0823416689.USD","LU1917777945.USD","LU1974910355.USD","LU0058720904.USD","BK4585","ENDO","LU2237438978.USD","LU0823434740.USD","LU2362541513.USD","PRGS","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640159010","title":"BRIEF-Parabilis Medicines - Estimated IPO Price Per Share Between $17 And $19 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2640159010","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640159010?lang=en_us&edition=fundamental","pubTime":"2026-06-04 18:32","pubTimestamp":1780569177,"startTime":"0","endTime":"0","summary":"BRIEF-Parabilis Medicines - Estimated IPO Price Per Share Between $17 And $19 - SEC FilingJune 4 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:PARABILIS MEDICINES - ESTIMATED IPO PRICE PER SHARE BE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nFWN42C01B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","LU0823434740.USD","LU2106854487.HKD","LU0882574055.USD","LU0109394709.USD","LU2362541513.USD","LU0289739699.SGD","BK4585","LU1917777945.USD","LU2362540622.SGD","LU0823434583.USD","LU2089984988.USD","LU0320765992.SGD","LU0058720904.USD","LU2468319806.SGD","REGN","LU0823416689.USD","LU1974910355.USD","LU2237438978.USD","LU2023250504.SGD","BK4139","LU0053666078.USD","LU0114720955.EUR","LU0889565916.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640615912","title":"Parabilis Medicines - Intends to Use About $150 Mln of IPO Proceeds to Continue Ongoing Clinical Development of Zolucatetide in Desmoid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2640615912","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640615912?lang=en_us&edition=fundamental","pubTime":"2026-06-04 18:18","pubTimestamp":1780568294,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nFWN42C01B:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2023250504.SGD","LU0109394709.USD","BK4139","LU0114720955.EUR","BK4588","LU2089984988.USD","LU0882574055.USD","LU0320765992.SGD","LU0058720904.USD","REGN","LU2362541273.HKD","LU0289739699.SGD","LU0823416689.USD","LU0823434583.USD","LU2362540622.SGD","BK4585","LU1917777945.USD","LU0889565916.HKD","LU2237438978.USD","LU0823434740.USD","LU2106854487.HKD","LU2362541513.USD","LU1974910355.USD","LU2468319806.SGD","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640591691","title":"Parabilis Medicines Inc Says Regeneron Pharmaceuticals Agreed to Buy About $75 Mln of Co's Common Stock in Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2640591691","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640591691?lang=en_us&edition=fundamental","pubTime":"2026-06-04 18:18","pubTimestamp":1780568294,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nFWN42C01B:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0823434583.USD","BK4588","LU0320765992.SGD","LU2106854487.HKD","REGN","BK4139","LU0882574055.USD","LU2089984988.USD","LU2468319806.SGD","LU0114720955.EUR","LU2362540622.SGD","LU0053666078.USD","LU0289739699.SGD","LU2362541273.HKD","LU2023250504.SGD","LU0889565916.HKD","LU0823416689.USD","LU1917777945.USD","LU1974910355.USD","LU0058720904.USD","BK4585","LU2237438978.USD","LU0823434740.USD","LU2362541513.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640918493","title":"Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2640918493","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640918493?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:47","pubTimestamp":1780519620,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  rose 2.66% to $618.95 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index  falling 0.74% to 7,553.68 and Dow Jones Industrial Average  falling 1.21% to 50,687.07.This was the stock's second consecutive day of gains.Regeneron Pharmaceuticals Inc. closed 24.62% below its 52-week high of $821.11, which the company achieved on January 9th.The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Amgen Inc.  rose 3.03% to $338.22, Moderna Inc.  rose 7.49% to $49.06, and Gilead Sciences Inc.  rose 1.11% to $128.99.Data source: Dow Jones Market Data, FactSet. Data compiled June 3, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126612604","title":"Movement Alert｜Regeneron Pharmaceuticals Rises 3.07% in Regular Trading, WHO Ebola Antibody Recommendation and CytomX Partnership Expansion Boost Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1126612604","media":"Market Focus","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126612604?lang=en_us&edition=fundamental","pubTime":"2026-06-04 00:36","pubTimestamp":1780504570,"startTime":"0","endTime":"0","summary":"On June 3, Regeneron Pharmaceuticals rose 3.07% in regular trading, trading at $621.42/share, with trading volume of approximately $211 million. Multiple positive catalysts converged to drive the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640183562","title":"BUZZ-U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2640183562","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640183562?lang=en_us&edition=fundamental","pubTime":"2026-06-03 23:42","pubTimestamp":1780501359,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the RunwayWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call n","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nL6N42B103:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARES","GTLB","GRRR","INCY","FICO","YUM","REGN","TBN","TGTX","GPN","THO","WCT","FDX","FLR","USAR","TTI","MMED","JZ","RJF","TE","CELC","TPL","CTMX","MLYS","STLD","NRXP","AADX","XOS","CETX","OLLI","LDOS","KKR","HIMS","COCP","MX","TISI","BX","GME","NOTV","MDT","OWL","AXSM","SDOT","WDC","RENT","GMEY","SMR","HGV","LUNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640020849","title":"CytomX Therapeutics Expands Cancer Therapy Partnership With Regeneron; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2640020849","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640020849?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:21","pubTimestamp":1780492882,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics  said Wednesday it is expanding a licensing agreement with Regeneron Pharmaceuticals  to develop conditionally activated bispecific cancer treatments.CytomX said it will receive a $37 million target nomination payment for two newly chosen development programs.Regeneron holds the right to select up to six more targets, bringing the overall potential milestone value of the broadened agreement to roughly $4 billion, CytomX said.Shares CytomX were more than 5% higher premarket trading, while Regeneron was down 0.5%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0823416689.USD","LU0889565916.HKD","LU2089984988.USD","LU2106854487.HKD","LU0058720904.USD","LU2362541273.HKD","LU2468319806.SGD","LU2237438978.USD","LU0823434583.USD","LU0882574055.USD","LU1974910355.USD","REGN","LU0114720955.EUR","CTMX","BK4588","LU1917777945.USD","LU0053666078.USD","BK4139","LU2362540622.SGD","LU0109394709.USD","LU2362541513.USD","LU0289739699.SGD","LU0320765992.SGD","LU0823434740.USD","LU2023250504.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640490101","title":"BUZZ-CytomX rises on expanded Regeneron deal with up to $4 billion in milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2640490101","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640490101?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:22","pubTimestamp":1780489374,"startTime":"0","endTime":"0","summary":"BUZZ-CytomX rises on expanded Regeneron deal with up to $4 billion in milestones** Shares of CytomX Therapeutics CTMX.O rise 3.5% to $3.27 premarket ** Co says it has expanded its licensing agreement with Regeneron Pharmaceuticals REGN.O to develop next-generation bispecific cancer therapies in a collaboration that could be worth up to about $4 billion** The partnership combines CytomX’s Probody platform with Regeneron's Veloci-Bi technology to create conditionally activated bispecific antibodies designed to target tumors while limiting damage to healthy tissue** As part of the expansion, CytomX will receive a $37 million payment after Regeneron selects two additional drug targets** Regeneron also secures option to choose up to six more targets under the collaboration** Regeneron will lead and fund preclinical and clinical development as well as commercialization, while CytomX is eligible to receive milestone payments tied to development, regulatory approvals and sales, as well as tier","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nL4N42B11W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","BK4588","LU2106854487.HKD","LU1917777945.USD","LU2362540622.SGD","BK4139","LU2023250504.SGD","LU0114720955.EUR","CTMX","LU2089984988.USD","LU0823416689.USD","LU0320765992.SGD","LU0109394709.USD","LU1974910355.USD","BK4585","LU2362541273.HKD","LU0289739699.SGD","REGN","LU0823434740.USD","LU2468319806.SGD","LU0882574055.USD","LU2362541513.USD","LU0058720904.USD","LU2237438978.USD","LU0889565916.HKD","LU0823434583.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640901118","title":"CytomX expands Regeneron bispecific cancer therapy collaboration, receives $37 million payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2640901118","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640901118?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:06","pubTimestamp":1780488385,"startTime":"0","endTime":"0","summary":"CytomX expanded its collaboration and licensing deal with Regeneron to develop conditionally activated bispecific cancer therapies.Regeneron will fund preclinical and clinical development, as well as commercialization, for programs covered under the expanded agreement.CytomX will receive a USD 37 million target selection payment tied to two additional programs.Regeneron secured an option to select up to six additional future targets.Milestones across nomination, development, regulatory, and sales could total about USD 4 billion; CytomX is also eligible for tiered global net sales royalties.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL2gW24C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2362541273.HKD","BK4585","IE00BN0W2W23.USD","LU0823434583.USD","LU0109394709.USD","LU0058720904.USD","NDAQ","LU0823434740.USD","SG9999014005.SGD","IE00BN0W2T93.GBP","LU2362541513.USD","BK4588","LU0289739699.SGD","LU2089984988.USD","LU2468319806.SGD","LU2095319765.USD","LU0053666078.USD","LU2237438978.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","REGN","IE00BKPKM429.USD","SG9999014013.SGD","LU0823416689.USD","LU0314104364.USD","SG9999014021.USD","CTMX","BK4139","BK4112","IE00BN0W2V16.EUR","LU0889565916.HKD","LU2210150020.SGD","IE00BGHQF748.EUR","LU2106854487.HKD","LU0882574055.USD","LU0114720955.EUR","LU1917777945.USD","LU1974910355.USD","LU2210149790.SGD","LU0320765992.SGD","LU2362540622.SGD","LU2023250504.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640636901","title":"CytomX Therapeutics - Regeneron Secures Option for 6 Additional Targets; Total Milestones up to About $4 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2640636901","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640636901?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:00","pubTimestamp":1780488002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA4G4MZG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2106854487.HKD","LU2089984988.USD","LU0823434583.USD","LU1974910355.USD","LU0823434740.USD","LU1917777945.USD","BK4588","LU0882574055.USD","LU2023250504.SGD","LU2362540622.SGD","BK4585","REGN","LU0320765992.SGD","LU2237438978.USD","LU0053666078.USD","LU0289739699.SGD","LU2362541273.HKD","CTMX","LU0058720904.USD","LU2362541513.USD","LU0109394709.USD","BK4139","LU2468319806.SGD","LU0823416689.USD","LU0114720955.EUR","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640016879","title":"CytomX Therapeutics - Eligible for Tiered Global Net Sales Royalties Under Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2640016879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640016879?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:00","pubTimestamp":1780488002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA4G4MZG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0058720904.USD","REGN","LU2362541273.HKD","LU2089984988.USD","LU2468319806.SGD","LU0889565916.HKD","LU1974910355.USD","CTMX","BK4585","LU0823434583.USD","LU2362540622.SGD","LU1917777945.USD","LU0823416689.USD","LU2237438978.USD","LU0053666078.USD","LU2023250504.SGD","BK4588","LU0823434740.USD","LU2106854487.HKD","LU0289739699.SGD","BK4139","LU2362541513.USD","LU0882574055.USD","LU0320765992.SGD","LU0109394709.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640125942","title":"Regeneron’s CLIO-1 Update: What a Completed Early Lymphoma Trial Means for REGN Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2640125942","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640125942?lang=en_us&edition=fundamental","pubTime":"2026-06-03 00:30","pubTimestamp":1780417812,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron’s CLIO-1 trial, officially titled “A Phase 1 Study...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regenerons-clio-1-update-what-a-completed-early-lymphoma-trial-means-for-regn-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regenerons-clio-1-update-what-a-completed-early-lymphoma-trial-means-for-regn-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2362541273.HKD","LU0823434740.USD","LU2106854487.HKD","LU0882574055.USD","LU0109394709.USD","LU2362541513.USD","LU0289739699.SGD","BK4585","LU1917777945.USD","LU2362540622.SGD","LU0823434583.USD","LU2089984988.USD","LU0320765992.SGD","BK4211","LU0058720904.USD","LU2468319806.SGD","REGN","LU0823416689.USD","LU1974910355.USD","LU2237438978.USD","LU2023250504.SGD","ISBC","BK4139","LU0053666078.USD","LU0114720955.EUR","LU0889565916.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640910738","title":"Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), Vera Therapeutics (VERA) and Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640910738","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640910738?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:00","pubTimestamp":1780401656,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IDEAYA Biosciences (IDYA), Vera Therapeutics (VERA) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ideaya-biosciences-idya-vera-therapeutics-vera-and-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ideaya-biosciences-idya-vera-therapeutics-vera-and-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0053666078.USD","LU2023250504.SGD","LU1917777945.USD","LU1974910355.USD","LU0320765992.SGD","BK4539","REGN","LU2089984988.USD","BK4139","LU2362541513.USD","LU0109394709.USD","LU2468319806.SGD","LU0128526141.USD","BK4581","BK4137","LU0882574055.USD","LU0889565916.HKD","LABU","LU2362541273.HKD","VERA","LU2324357040.USD","IDYA","LU0823434740.USD","XBI","LU0289739699.SGD","LU0029874061.USD","BK4588","BK4585","HCSG","LU2106854487.HKD","LU0058720904.USD","LU2237438978.USD","LU2362540622.SGD","XLV","LU0823434583.USD","LU0114720955.EUR","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640962966","title":"Regeneron Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2640962966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640962966?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:45","pubTimestamp":1780346700,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  slipped 2.30% to $600.66 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 0.26% to 7,599.96 and the Dow Jones Industrial Average  rising 0.09% to 51,078.88.This was the stock's seventh consecutive day of losses.Regeneron Pharmaceuticals Inc. closed 26.85% short of its 52-week high of $821.11, which the company reached on January 9th.The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Amgen Inc.  fell 2.27% to $329.13, Moderna Inc.  fell 2.39% to $46.06, and Gilead Sciences Inc.  fell 2.48% to $131.10.Trading volume  eclipsed its 50-day average volume of 877,224.Data source: Dow Jones Market Data, FactSet. Data compiled June 1, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640595356","title":"FACTBOX-What Bundibugyo Ebola vaccines and treatments are under development","url":"https://stock-news.laohu8.com/highlight/detail?id=2640595356","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640595356?lang=en_us&edition=fundamental","pubTime":"2026-06-01 18:26","pubTimestamp":1780309603,"startTime":"0","endTime":"0","summary":"FACTBOX-What Bundibugyo Ebola vaccines and treatments are under developmentAdds details on CEPI funding and Moderna's candidate in paragraphs 13, 17 and 21By Mariam Sunny and Jennifer Rigby","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nL4N4290OV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN","LU2112291526.USD","IE00B19Z3B42.SGD","LU2106854487.HKD","MRNY","LU1430594728.SGD","LU2237443622.USD","REGN","LU2023250843.SGD","LU0882574055.USD","IE00BJJMRZ35.SGD","LU0985320562.USD","LU1989772840.SGD","LU2237443382.USD","IE0002141913.USD","LU0320765646.SGD","SG9999001440.SGD","SG9999015978.USD","BK4588","LU0889565916.HKD","LU0432979614.USD","LU2237443895.HKD","LU2089984988.USD","LU1923622614.USD","LU1917777945.USD","LU1674673428.USD","LU2362541273.HKD","LU0109394709.USD","LU0965508806.USD","IE00BZ1G4Q59.USD","LU1934455863.HKD","LU0859254822.USD","LU0122379950.USD","BK4007","LU0234572021.USD","LU0868494708.USD","LU0058720904.USD","LU1989771016.USD","LU2361044865.SGD","LU0130102774.USD","MRNX","SG9999014575.USD","LU2456880835.USD","IE00BLSP4452.SGD","LU1974910355.USD","LU2125909593.SGD","LU1778281490.HKD","LU0965509283.SGD","LU1839511570.USD","LU1929549753.HKD","LU1989772923.USD","SG9999002224.SGD","IE00BSNM7G36.USD","IE00BFTCPJ56.SGD","LU0265550359.USD","LU0823434583.USD","LU0266013472.USD","LU2491050071.SGD","IE00BN8TJ469.HKD","BK4532","SG9999014542.SGD","GILD","LU1066051225.USD","SGXZ57979304.SGD","BK4568","IE00BJT1NW94.SGD","LU2361045086.USD","LU1699723380.USD","LU1674673691.USD","LU1934455277.USD","LU2324357040.USD","SG9999014567.USD","LU2462157665.USD","LU0942090050.USD","LU0106261372.USD","SG9999001176.USD","LU2125909247.SGD","MRNA","LU1066053197.SGD","LU2023250504.SGD","BK4559","LU0053666078.USD","LU0477156953.USD","LU2125154778.USD","LU1037948541.HKD","LU0648001328.SGD","LU2361044949.HKD","IE0009355771.USD","LU0234570918.USD","LU2237443549.SGD","SG9999015952.SGD","IE00B7SZLL34.SGD","SG9999015358.SGD","IE00B4R5TH58.HKD","LU0861579265.USD","SG9999015986.USD","MRK","SG9999014559.SGD","BK4566","BK4550","LU1291159041.SGD","LU0130517989.USD","LU2491049909.HKD","IE00B19Z3581.USD","LU2357627491.SGD","IE00B3T34201.USD","SG9999002232.USD","LU1983299246.USD","SG9999013999.USD","LU1035773651.USD","LU1116320901.HKD","LU1829250122.USD","LU2491050154.USD","LU0980610538.SGD","LU0203347892.USD","BK4534","BK4533","BK4548","LU0006306889.USD","LU0211331839.USD","BK4583","LU1093756325.SGD","LU1057294990.SGD","LU1934455194.USD","LU0823416689.USD","LU1066051811.HKD","LU0070302665.USD","LU2433249047.HKD","LU2237438978.USD","LU1023059063.AUD","LU2468319806.SGD","LU1093756168.USD","LU0098860793.USD","LU1571399168.USD","IE00BLSP4239.USD","LU1201861249.SGD","IE00BBT3K403.USD","LU2417539215.USD","LU0823434740.USD","LU1037948897.HKD","LU2362540622.SGD","LU2236285917.USD","IE00B1BXHZ80.USD","LU1941712264.USD","IE000M9KFDE8.USD","LU0265550946.USD","LU1116320737.USD","LU2461242641.AUD","LU2087621335.USD","LU0203345920.USD","LU0238689110.USD","BK4516","LU1069347547.HKD","LU1162221912.USD","LU0289739699.SGD","LU2362541513.USD","BK4551","LU2237443978.SGD","LU0868494617.USD","BK4501","LU0320765489.SGD","SG9999015945.SGD","IE00B2B36J28.USD","AZNH","LU0965509101.SGD","BK4139","LU1941712348.USD","LU2237443465.HKD","IE00BKVL7J92.USD","LU0114720955.EUR","LU1061106388.HKD","LU0320765992.SGD","LU1585245621.USD","SG9999001176.SGD","LU0965509010.AUD","IE0002270589.USD","LU2125154935.USD","SG9999015341.SGD","LU1066051498.USD","BK4585","LU2360032135.SGD","LU0208291251.USD","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639086602","title":"WHO Ebola Trial Puts Regeneron’s Maftivimab Platform In Investor Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2639086602","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639086602?lang=en_us&edition=fundamental","pubTime":"2026-05-31 09:08","pubTimestamp":1780189727,"startTime":"0","endTime":"0","summary":"World Health Organization recommends Regeneron’s maftivimab for priority evaluation in clinical trials for the current Bundibugyo ebolavirus outbreak.\nMaftivimab is a component of Inmazeb, which is already approved for Zaire ebolavirus treatment.\nThe recommendation positions Regeneron Pharmaceuticals (NasdaqGS:REGN) within an active emergency response affecting multiple African countries.\n\nRegeneron Pharmaceuticals, traded as NasdaqGS:REGN, is widely known for its antibody platforms and...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/who-ebola-trial-puts-regenerons-maftivimab-platform-in-inves","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/who-ebola-trial-puts-regenerons-maftivimab-platform-in-inves","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2106854487.HKD","LU2089984988.USD","LU0823434583.USD","LU1974910355.USD","LU0823434740.USD","LU1917777945.USD","BK4588","LU0882574055.USD","LU2023250504.SGD","LU2362540622.SGD","BK4585","REGN","LU0320765992.SGD","LU2237438978.USD","LU0053666078.USD","LU0289739699.SGD","LU2362541273.HKD","LU0058720904.USD","LU2362541513.USD","LU0109394709.USD","BK4139","LU2468319806.SGD","LU0823416689.USD","LU0114720955.EUR","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639677102","title":"Regeneron Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2639677102","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639677102?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:46","pubTimestamp":1780087560,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  shed 1.08% to $614.78 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index  rising 0.22% to 7,580.06 and the Dow Jones Industrial Average  rising 0.72% to 51,032.46.This was the stock's sixth consecutive day of losses.Regeneron Pharmaceuticals Inc. closed 25.13% short of its 52-week high of $821.11, which the company achieved on January 9th.The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Amgen Inc.  rose 0.09% to $336.79, Moderna Inc.  fell 0.80% to $47.19, and Gilead Sciences Inc.  fell 1.31% to $134.43.Data source: Dow Jones Market Data, FactSet. Data compiled May 29, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":0.0336},{"period":"1month","weight":-0.1187},{"period":"3month","weight":-0.1637},{"period":"6month","weight":-0.1154},{"period":"1year","weight":0.3154},{"period":"ytd","weight":-0.1767}],"compareEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.2437},{"period":"ytd","weight":0.0816}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.514286,"avgChangeRate":0.03675},{"month":2,"riseRate":0.428571,"avgChangeRate":0.086855},{"month":3,"riseRate":0.457143,"avgChangeRate":-0.043382},{"month":4,"riseRate":0.457143,"avgChangeRate":0.014275},{"month":5,"riseRate":0.611111,"avgChangeRate":0.052257},{"month":6,"riseRate":0.444444,"avgChangeRate":0.007491},{"month":7,"riseRate":0.657143,"avgChangeRate":0.052646},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.043803}],"exchange":"NASDAQ","name":"Regeneron Pharmaceuticals","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regeneron Pharmaceuticals,REGN,Regeneron Pharmaceuticals股票,Regeneron Pharmaceuticals股票老虎,Regeneron Pharmaceuticals股票老虎国际,Regeneron Pharmaceuticals行情,Regeneron Pharmaceuticals股票行情,Regeneron Pharmaceuticals股价,Regeneron Pharmaceuticals股市,Regeneron Pharmaceuticals股票价格,Regeneron Pharmaceuticals股票交易,Regeneron Pharmaceuticals股票购买,Regeneron Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}